Literature DB >> 11206041

Analytical validation for a series of marker compounds used to assess renal drug elimination processes.

A J McLachlan1, A S Gross, J L Beal, I Minns, S E Tett.   

Abstract

Renal drug elimination is determined by glomerular filtration, tubular secretion, and tubular reabsorption. Changes in the integrity of these processes influence renal drug clearance, and these changes may not be detected by conventional measures of renal function such as creatinine clearance. The aim of the current study was to examine the analytic issues needed to develop a cocktail of marker drugs (fluconazole, rac-pindolol, para-aminohippuric acid, sinistrin) to measure simultaneously the mechanisms contributing to renal clearance. High-performance liquid chromatographic methods of analysis for fluconazole, pindolol, para-aminohippuric acid, and creatinine and an enzymatic assay for sinistrin were developed or modified and then validated to allow determination of each of the compounds in both plasma and urine in the presence of all other marker drugs. A pilot clinical study in one volunteer was conducted to ensure that the assays were suitable for quantitating all the marker drugs to the sensitivity and specificity needed to allow accurate determination of individual renal clearances. The performance of all assays (plasma and urine) complied with published validation criteria. All standard curves displayed linearity over the concentration ranges required, with coefficients of correlation greater than 0.99. The precision of the interday and intraday variabilities of quality controls for each marker in plasma and urine were all less than 11.9% for each marker. Recoveries of markers (and internal standards) in plasma and urine were all at least 90%. All markers investigated were shown to be stable when plasma or urine was frozen and thawed. For all the assays developed, there were no interferences from other markers or endogenous substances. In a pilot clinical study, concentrations of all markers could be accurately and reproducibly determined for a sufficient duration of time after administration to calculate accurate renal clearance for each marker. This article presents details of the analytic techniques developed for measuring concentrations of marker drugs for different renal elimination processes administered as a single dose to define the processes contributing to renal drug elimination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206041     DOI: 10.1097/00007691-200102000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 2.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

3.  GFR may not accurately predict aspects of proximal tubule drug handling.

Authors:  T L Putt; Stephen B Duffull; J B W Schollum; R J Walker
Journal:  Eur J Clin Pharmacol       Date:  2014-08-20       Impact factor: 2.953

4.  Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.

Authors:  A S Gross; A J McLachlan; I Minns; J B Beal; S E Tett
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

5.  Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.

Authors:  Jens Rengelshausen; Christoph Göggelmann; Jürgen Burhenne; Klaus-Dieter Riedel; Jochen Ludwig; Johanna Weiss; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 6.  Principles and clinical application of assessing alterations in renal elimination pathways.

Authors:  Susan E Tett; Carl M J Kirkpatrick; Annette S Gross; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds.

Authors:  Andrew A Udy; Paul Jarrett; Janine Stuart; Melissa Lassig-Smith; Therese Starr; Rachel Dunlop; Steven C Wallis; Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care       Date:  2014-11-29       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.